drugset / Trial / NCT04279938
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Phase 1
Withdrawn
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC · collabMundipharma-EDO GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
Safety run-in (part 1): Relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL) Main study (part 2): Relapsed or refractory diffuse large B-cell lymphoma
Timeline
- Start
- 2018-09
- Primary completion
- 2020-03
- Completion
- 2021-01
Outcome
Outcome not reported
Stopped: “Safety data on drug”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tinostamustinein | Unknown | — | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |